<SEC-DOCUMENT>0001193125-22-211332.txt : 20220803
<SEC-HEADER>0001193125-22-211332.hdr.sgml : 20220803
<ACCEPTANCE-DATETIME>20220803164247
ACCESSION NUMBER:		0001193125-22-211332
CONFORMED SUBMISSION TYPE:	S-3ASR
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20220803
DATE AS OF CHANGE:		20220803
EFFECTIVENESS DATE:		20220803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evolent Health, Inc.
		CENTRAL INDEX KEY:			0001628908
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT SERVICES [8741]
		IRS NUMBER:				320454912
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3ASR
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-266495
		FILM NUMBER:		221133291

	BUSINESS ADDRESS:	
		STREET 1:		800 NORTH GLEBE RD, SUITE 500
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22203
		BUSINESS PHONE:		571-389-6000

	MAIL ADDRESS:	
		STREET 1:		800 NORTH GLEBE RD, SUITE 500
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22203
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3ASR
<SEQUENCE>1
<FILENAME>d386518ds3asr.htm
<DESCRIPTION>S-3ASR
<TEXT>
<HTML><HEAD>
<TITLE>S-3ASR</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on August 3, 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>
</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-3</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Evolent Health, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Its Charter) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">32-0454912</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction of<BR>incorporation or organization)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer<BR>Identification No.)</B></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>800 N. Glebe Road, Suite 500 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Arlington, Virginia 22203 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(571) <FONT STYLE="white-space:nowrap">389-6000</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#146;s Principal Executive Offices) </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Jonathan Weinberg, Esq. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>General Counsel </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>800 N.
Glebe Road, Suite 500 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Arlington, Virginia 22203 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(571) <FONT STYLE="white-space:nowrap">389-6000</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service) </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Copy to: </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Elizabeth
Morgan, Esq. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>King&nbsp;&amp; Spalding LLP </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>1185 Avenue of the Americas </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10036 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">556-2100</FONT> </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>Approximate date of
commencement of proposed sale to the public: From time to time after this Registration Statement becomes effective. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If the only securities being
registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If any of
the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans,
check the following box.&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the
Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this Form is a registration
statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or
additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company, or an emerging growth company. See the definitions of &#147;large accelerated
filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744; (Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging growth company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g386518g03s13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Evolent Health, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>CLASS A COMMON STOCK </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus covers the
resale by selling stockholders of shares of our Class&nbsp;A common stock, par value $0.01 per share (&#147;Class&nbsp;A common stock&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling
stockholders, who will be named in a prospectus supplement, may offer and sell shares of our Class&nbsp;A common stock, from time to time in amounts, at prices, and on terms that will be determined at the time of any such offering. We will not
receive any proceeds from the sale of our Class&nbsp;A common stock by the selling stockholders. This prospectus describes some of the general terms that may apply to our Class&nbsp;A common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each time any of the selling stockholders offer and sell shares of our Class&nbsp;A common stock, such selling stockholders will provide a supplement to this
prospectus that contains specific information about the offering and the selling stockholders, as well as the amounts and prices of the Class&nbsp;A common stock to be offered and sold. The applicable prospectus supplement may also add, update or
change information contained in this prospectus with respect to that offering. You should read this prospectus and the accompanying prospectus supplement, as well as the documents incorporated by reference herein or therein, carefully before you
make your investment decision. This prospectus may not be used to offer and sell shares of our Class&nbsp;A common stock unless accompanied by a prospectus supplement or a free writing prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may offer and sell the Class&nbsp;A common stock described in this prospectus and any prospectus supplement to or through one or more
underwriters, dealers and agents, or directly to purchasers, or through a combination of these methods. If any underwriters, dealers or agents are involved in the sale of our Class&nbsp;A common stock, their names and any applicable purchase price,
fee, commission or discount arrangement between or among them will be set forth, or will be calculable from the information set forth, in the applicable prospectus supplement. See the sections of this prospectus entitled &#147;About this
Prospectus&#148; and &#147;Plan of Distribution&#148; for more information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Class&nbsp;A common stock is listed on The New York Stock Exchange (the
&#147;NYSE&#148;) under the symbol &#147;EVH.&#148; The last reported closing sale price of our Class&nbsp;A common stock on August 2, 2022 was $35.21 per share. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in shares of our
Class&nbsp;A common stock involves risk. See &#147;<A HREF="#tx386518_2">Risk Factors</A>&#148; beginning on page 2. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of the shares of our Class&nbsp;A common stock or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is August 3, 2022 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx386518_1">About this Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx386518_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx386518_3">Cautionary Statement Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx386518_4">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx386518_5">Incorporation by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx386518_6">About Us</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx386518_7">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx386518_8">Selling Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx386518_9">Description of Class&nbsp;A Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx386518_10">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx386518_11">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx386518_12">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx386518_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed as a &#147;well-known seasoned issuer,&#148; or &#147;WKSI,&#148; as defined in Rule 405 of
the Securities Act, with the Securities and Exchange Commission (the &#147;SEC&#148;) using the &#147;automatic shelf&#148; registration process. Under the automatic shelf registration process, the selling stockholders may, from time to time, offer
and/or sell our Class&nbsp;A common stock in one or more offerings or resales. This prospectus provides you with a general description of the Class&nbsp;A common stock that the selling stockholders may offer. Each time the selling stockholders offer
and sell shares of our Class&nbsp;A common stock using this prospectus, we will provide a prospectus supplement and attach it to this prospectus and may also provide you with a free writing prospectus. The prospectus supplement and any free writing
prospectus will contain more specific information about the shares of Class&nbsp;A common stock being offered and sold and the specific terms of that offering. The prospectus supplement may also add, update, change, or clarify information contained
in or incorporated by reference into this prospectus. Any statement that we make in this prospectus will be modified or superseded by any inconsistent statement made by us or the selling stockholders in a prospectus supplement. If the information in
this prospectus is inconsistent with the information in any applicable prospectus supplement, any applicable amendment or any applicable free writing prospectus, you should rely on the information in that prospectus supplement, amendment or free
writing prospectus; provided, that if any statement in one of these documents is inconsistent with a statement in another document having a later date&#151;for example, a document incorporated by reference into this prospectus or any prospectus
supplement or any applicable free writing prospectus&#151;the statement in the document having the later date modifies or supersedes the earlier statement. Before making an investment in our Class&nbsp;A common stock, you should read both this
prospectus and, if applicable, any prospectus supplement or any free writing prospectus, as well as the other information contained or incorporated by reference in this prospectus or in any prospectus supplement hereto. See &#147;Where You Can Find
More Information&#148; and &#147;Incorporation by Reference&#148; for more information. This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for
complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of the documents referred to herein have been filed, or will be filed or incorporated by reference, as exhibits to the registration statement
of which this prospectus is a part. The registration statement, including the exhibits and documents incorporated or deemed incorporated by reference in this prospectus, can be read on the SEC website mentioned under the heading &#147;Where You Can
Find More Information.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither we nor any selling stockholders have authorized anyone to provide you with information other than that contained
in this prospectus or in any accompanying prospectus supplement or free writing prospectus prepared by or on behalf of us or to which we have referred you. We and any selling stockholders take no responsibility for, and can provide no assurance as
to the reliability of, any other information that others may give you. This prospectus or any accompanying prospectus supplement does not constitute an offer to sell or a solicitation of an offer to buy any shares of our Class&nbsp;A common stock
other than the registered shares to which they relate, and this prospectus or any accompanying prospectus supplement does not constitute an offer to sell or the solicitation of an offer to buy shares in any jurisdiction where, or to any person to
whom, it is unlawful to make such an offer or solicitation. You should not assume that the information contained in this prospectus and any accompanying prospectus supplement is correct on any date after the respective dates of the prospectus and
such prospectus supplement or supplements, as applicable, even though this prospectus and such prospectus supplement or supplements are delivered or shares are sold pursuant to the prospectus and such prospectus supplement or supplements at a later
date. Since the respective dates of the prospectus contained in this registration statement and any accompanying prospectus supplement, our business, financial condition, results of operations and prospects may have changed. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated or required by the context, references in this prospectus to &#147;Evolent,&#148; &#147;we,&#148; &#147;our,&#148;
&#147;us,&#148; &#147;our company&#148; and &#147;the company&#148; refer to Evolent Health, Inc., a Delaware corporation, together with its consolidated subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx386518_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An investment in our Class&nbsp;A common stock involves risks. You should carefully consider the risk factors incorporated by reference to our most recent
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and in subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> together with the other information contained in this prospectus, or any prospectus
supplement or incorporated by reference herein or therein, before purchasing shares of our Class&nbsp;A common stock. See &#147;Where You Can Find More Information&#148; for information about how to obtain a copy of these documents. If any of those
risks are realized, our business, financial condition, operating results and prospects could be materially and adversely affected. Additional risks not presently known to us or that we currently deem immaterial may also impair our business
operations. In that event, the price of our Class&nbsp;A common stock could decline, and you could lose part or all of your investment. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx386518_3"></A>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain statements made in this prospectus and the documents incorporated herein by reference and in other written or oral statements made by us or on our
behalf are &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995 (&#147;PSLRA&#148;). A forward-looking statement is a statement that is not a historical fact and, without limitation,
includes any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like: &#147;believe,&#148; &#147;anticipate,&#148; &#147;expect,&#148; &#147;estimate,&#148; &#147;aim,&#148;
&#147;predict,&#148; &#147;potential,&#148; &#147;continue,&#148; &#147;plan,&#148; &#147;project,&#148; &#147;will,&#148; &#147;should,&#148; &#147;shall,&#148; &#147;may,&#148; &#147;might&#148; and other words or phrases with similar meaning in
connection with a discussion of future operating or financial performance. We claim the protection afforded by the safe harbor for forward-looking statements provided by the PSLRA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should not rely on forward-looking statements as predictions of future events. We have based the forward-looking statements contained in this prospectus,
and any accompanying prospectus supplement, primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, and results of operations. The outcome of the events
described in these forward-looking statements is subject to risks, uncertainties and other factors described in the section titled &#147;Risk Factors&#148; and elsewhere in this prospectus and any accompanying prospectus supplement. Moreover, we
operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements
contained in this prospectus and any accompanying prospectus supplement. The results, events and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events or circumstances could differ
materially from those described in the forward-looking statements. Please refer to the &#147;Risk Factors&#148; section in this prospectus, any accompanying prospectus supplement, and in Part I, Item 1A of our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, and, to the extent applicable, our Quarterly Reports on Form 10-Q. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, it is not possible to assess the effect of all risk factors on our businesses or the extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in any forward-looking statements. The forward-looking statements made in this prospectus and any accompanying prospectus supplement relate only to events as of the date on which the
statements are made. We undertake no obligation to update any forward-looking statements made in this prospectus and any accompanying prospectus supplement to reflect events or circumstances after the date of this prospectus and any accompanying
prospectus supplement or to reflect new information or the occurrence of unanticipated events, except as required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For further discussion of
factors that could materially affect the outcome of our forward-looking statements, see &#147;Item 1A. Risk Factors&#148; in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> which are incorporated by reference in this
prospectus, and, to the extent applicable, our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and any accompanying prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx386518_4"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the information and reporting requirements of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), and,
accordingly, file annual, quarterly and periodic reports, proxy statements and other information with the SEC. Our SEC filings, including our registration statement, are available to you, free of charge, on the SEC&#146;s website at www.sec.gov. Our
SEC filings will also be available on our website at ir.evolenthealth.com. The information contained on or linked to or from our website is not incorporated by reference into this prospectus or the registration statement of which they form a part.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed with the SEC an automatic shelf registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> including exhibits filed with
the registration statement of which this prospectus supplement is a part, under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), with respect to the shares of our Class&nbsp;A common stock registered hereby. This prospectus
and any applicable prospectus supplements do not contain all of the information set forth in the registration statement and exhibits to the registration statement. For further information with respect to our Company and the shares of our
Class&nbsp;A common stock registered hereby, reference is made to the registration statement, including the exhibits to the registration statement. Statements contained in this prospectus and any applicable prospectus supplement as to the contents
of any contract or other document referred to in this prospectus and any applicable prospectus supplement are not necessarily complete and, where that contract is an exhibit to the registration statement, each statement is qualified in all respects
by the exhibit to which the reference relates. Copies of the registration statement, including the exhibits to the registration statement, may be reviewed through the SEC&#146;s website, as described above. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx386518_5"></A>INCORPORATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; certain information into this prospectus from certain documents that we filed with the SEC prior to
the date of this prospectus and that we will file in the future. By incorporating by reference, we are disclosing important information to you by referring you to documents we have filed, or will file, separately with the SEC. The information
incorporated by reference is deemed to be part of this prospectus, except for information incorporated by reference that is modified or superseded by information contained in this prospectus or in any other subsequently filed document that also is
incorporated by reference herein. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to be part of this prospectus. These documents contain or will contain important information about us, our business
and our financial performance. The following documents are incorporated by reference into this prospectus, except for any document or portion thereof deemed to be furnished and not filed in accordance with SEC rules: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1628908/000162890822000027/evh-20211231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2021, filed with the SEC on February&nbsp;24, 2022 (our &#147;2021 <FONT STYLE="white-space:nowrap">10-K&#148;);</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended
March&nbsp;31, 2022 and June&nbsp;30, 2022, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1628908/000162890822000063/evh-20220331.htm">May&nbsp;
5, 2022</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1628908/000162890822000098/evh-20220630.htm">August&nbsp;3, 2022</A>, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The portions of our <A HREF="http://www.sec.gov/Archives/edgar/data/1628908/000119312522133588/d326880ddef14a.htm">Definitive
 Proxy Statement </A>on Schedule 14A filed with the SEC on April&nbsp;29, 2022 that are incorporated by reference into Part III of our 2021 <FONT STYLE="white-space:nowrap">10-K;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The description of our Class&nbsp;
A common stock included in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1628908/000119312515214021/d936600d8a12b.htm">Form <FONT STYLE="white-space:nowrap">8-A</FONT></A> filed with the SEC on June&nbsp;5, 2015, as
updated by <A HREF="http://www.sec.gov/Archives/edgar/data/1628908/000162890822000027/evh10-kexhibit46.htm">Exhibit 4.6</A> to our 2021 <FONT STYLE="white-space:nowrap">10-K,</FONT> and any amendment or report filed with the SEC for the purpose of
updating such description; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1628908/000162890822000012/evh-20220210.htm">February&nbsp;11,
 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1628908/000162890822000050/evh-20220301.htm">March&nbsp;
7, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1628908/000162890822000067/evh-20220609.htm">June&nbsp;
9, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1628908/000162890822000088/evh-20220624.htm">June&nbsp;
29, 2022</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1628908/000162890822000093/evh-20220801.htm">August&nbsp;2, 2022</A> (other than any portions thereof deemed furnished and not filed).
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, all documents that we subsequently file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, after
the date of this prospectus and prior to the termination of each offering under this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prospectus, shall be deemed to be incorporated by reference into this prospectus. We are not, however, incorporating, in each case, any documents (or portions thereof) or information that we are
deemed to furnish and not file in accordance with SEC rules unless expressly stated otherwise. Any statement in this prospectus, in any prospectus supplement, or in any document incorporated by reference that is different from any statement
contained in any later-filed document should be regarded as changed by that later statement. Once so changed, the earlier statement is no longer considered part of this prospectus or any prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information relating to us contained in this prospectus does not purport to be comprehensive and should be read together with the information contained in
the documents incorporated or deemed to be incorporated by reference into this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you request, either orally or in writing, we will provide
you with a copy of any or all documents that are incorporated by reference herein. Such documents will be provided to you free of charge, but will not contain any exhibits, unless those exhibits are incorporated by reference into the document.
Requests can be made by writing to Investor Relations at 800 N. Glebe Road, Suite 500, Arlington, Virginia 22203 or by phone at (571) <FONT STYLE="white-space:nowrap">389-6000.</FONT> The documents may also be accessed on our website at
ir.evolenthealth.com. Information contained on our website is not incorporated by reference into this prospectus and you should not consider information contained on our website to be part of this prospectus or any prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx386518_6"></A>ABOUT US </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evolent Health, Inc. is a holding company whose principal asset is all of the Class&nbsp;A common units it holds in Evolent Health LLC, and its only business
is to act as sole managing member of Evolent Health LLC. Substantially all of our operations are conducted through Evolent Health LLC and its consolidated subsidiaries. The financial results of Evolent Health LLC are consolidated in the financial
statements of Evolent Health, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a market leader in the new era of value-based care, in which the delivery of health care is increasingly funded
by <FONT STYLE="white-space:nowrap">at-risk</FONT> payment models. We provide integrated solutions to both health care providers, including independent physicians and health systems, as well as payers, including health plans and other risk-bearing
organizations, with a common end: to improve health care quality and outcomes while reducing cost. We consider value-based care to be the necessary convergence of health care payment and delivery. We believe the pace of this convergence is
accelerating, driven by price pressure in traditional FFS health care, a market environment that is incentivizing value-based care models, growth in consumer-focused insurance programs, such as Medicare Advantage and managed Medicaid, and innovation
in data and technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We manage our operations and allocate resources across two reportable segments: Evolent Health Services (&#147;EHS&#148;) and
Clinical Solutions. The Company&#146;s EHS segment provides an integrated administrative and clinical platform for health plan administration and population health management. Our Clinical Solutions segment addresses a broad spectrum of clinical
needs, with tailored solutions for Specialty Care Management in Oncology and Cardiology and holistic Total Cost of Care improvement. Our economic opportunity in the Clinical Solutions segment, which we believe to be significant, is largely based on
(a)&nbsp;the total amount of medical expenses under management, and (b)&nbsp;the amount of savings we are able to generate relative to a benchmark or target. These partnerships, which we refer to as performance-based arrangements, include both
capitation and shared savings arrangements. We also generate Clinical Solutions revenue by providing our technology and services platform on a fee basis. We go to market for our Specialty Care Management under the brand name New Century Health, and
for our Total Cost of Care solution under the brand name Evolent Care Partners. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evolent was founded in 2011 by members of our management team, University of Pittsburgh Medical Center (&#147;UPMC&#148;), an integrated delivery system in
Pittsburgh, Pennsylvania, and The Advisory Board Company, to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enable providers to pursue a value-based business model and evolve their competitive position and market opportunity. Since that time, we have grown both organically and through acquisitions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 800 N. Glebe Road, Suite 500, Arlington, Virginia 22203. Our telephone number is (571) <FONT
STYLE="white-space:nowrap">389-6000.</FONT> Our website address is www.evolenthealth.com. The information contained on, or that can be accessed through, our website is not incorporated by reference into this prospectus, and you should not consider
any information contained on, or that can be accessed through, our website as part of this prospectus or in deciding whether to purchase our Class&nbsp;A common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx386518_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will not receive any proceeds from the sale of our Class&nbsp;A common stock by the selling stockholders. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx386518_8"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information about selling stockholders, including their identities and the number of shares of Class&nbsp;A common stock registered on their behalf, will be
set forth in a prospectus supplement, in a post-effective amendment or in documents incorporated by reference into this prospectus that we file with the SEC. No selling stockholder shall sell any shares of our Class&nbsp;A common stock pursuant to
this prospectus until we have identified such selling stockholder and the shares being offered for resale by such selling stockholder in a subsequent prospectus supplement or in a post-effective amendment. However, selling stockholders may sell or
transfer all or a portion of their shares of our Class&nbsp;A common stock pursuant to any available exemption from the registration requirements of the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx386518_9"></A>DESCRIPTION OF CLASS A COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following sets forth certain general terms of the capital stock of Evolent Health, Inc. This information may not be complete in all respects and is
qualified in its entirety by reference to the General Corporation Law of the State of Delaware (the &#147;DGCL&#148;) and our certificate of incorporation and <FONT STYLE="white-space:nowrap">by-laws.</FONT> Copies of our certificate of
incorporation and <FONT STYLE="white-space:nowrap">by-laws</FONT> have been filed with the SEC and are incorporated by reference as exhibits to the registration statement of which this prospectus is a part. See &#147;Where You Can Find More
Information.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of
incorporation provides that we may issue up to 750,000,000 shares of Class&nbsp;A common stock, par value $0.01 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in our certificate of incorporation, or required by law, the holders of Class&nbsp;A common stock are entitled to one vote per
share on all matters to be voted upon by the stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividend and Liquidation Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to preferences that may be applicable to any outstanding preferred stock, the holders of Class&nbsp;A common stock are entitled to receive ratably such
dividends, if any, as may be declared from time to time by the board of directors out of funds legally available therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently anticipate that
we will retain all of our future earnings for use in the expansion and operation of our business and do not anticipate paying any cash dividends in the foreseeable future. The declaration and payment of all future dividends to holders of our
Class&nbsp;A common stock will be at the discretion of our board of directors and will depend on many factors, including our financial condition, earnings, legal requirements and any debt agreements we are then party to, and other factors our board
of directors deems relevant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of liquidation, dissolution or winding up of the Company, the holders of Class&nbsp;A common stock are entitled
to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock, if any, then outstanding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of our Class&nbsp;A common
stock have no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the Class&nbsp;A common stock. The rights, preferences and privileges of holders of our Class&nbsp;A common
stock are subject to those of the holders of any shares of our preferred stock we may issue in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Election and Removal of Directors;
Vacancies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors consists of up to 10 directors, excluding any directors elected by holders of any preferred stock pursuant to
provisions applicable in the case of defaults and subject to applicable laws and stock exchange regulations. The exact number of directors will be fixed from time to time by resolution of the board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with our certificate of incorporation and our <FONT STYLE="white-space:nowrap">by-laws,</FONT> our board of directors currently consists of 10
members. Prior to the 2023 annual meeting of stockholders, our board of directors is divided into three classes of directors, as nearly equal in number as possible. Any director elected prior to the date of the 2021 annual meeting of stockholders
will serve for a three-year term expiring on the date of the third annual meeting of stockholders following the annual meeting of stockholders at which that Director was elected. Each director </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
elected at the 2021 annual meeting of stockholders was elected for a <FONT STYLE="white-space:nowrap">one-year</FONT> term expiring at the 2022 annual meeting of stockholders. Each director
elected at the 2022 annual meeting of stockholders will be elected for a <FONT STYLE="white-space:nowrap">one-year</FONT> term expiring at the 2023 annual meeting of stockholders. At the 2023 annual meeting of stockholders and at each annual meeting
of stockholders thereafter, all directors will be elected for a <FONT STYLE="white-space:nowrap">one-year</FONT> term expiring at the next annual meeting of stockholders. There is no limit on the number of terms a director may serve on our board of
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with our IPO, we entered into a stockholders agreement which contains provisions related to the composition of our board of
directors, the committees of our board of directors and our corporate governance. Under the stockholders agreement, for so long as UPMC owns at least 40% of the shares of common stock held by it following the completion of our IPO, such stockholder
will be entitled to nominate two directors to serve on our board of directors. When such stockholder owns less than 40% but at least 5% of the shares of common stock held by it following the completion of our IPO, such stockholder will be entitled
to nominate one director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and our <FONT STYLE="white-space:nowrap">by-laws</FONT> provide that prior to the date of the
2023 annual meeting of stockholders, any director or the entire Board may be removed only for cause and only upon the affirmative vote of holders of at least 75% of the total voting power of all the then outstanding shares of capital stock entitled
to vote generally in the election of directors, voting together as a single class. On or after the date of the 2023 annual meeting of stockholders, any director or the entire Board may be removed, at any time, with or without cause, by the
affirmative vote of the holders of at least a majority of the voting power of the outstanding shares of Company&#146;s capital stock entitled to vote generally in the election of directors, voting together as a single class, subject to the terms of
the Stockholders Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, our certificate of incorporation and our <FONT STYLE="white-space:nowrap">by-laws</FONT> provide that any newly
created directorship on the board of directors that results from an increase in the number of directors and any vacancy occurring on the board of directors shall be filled only by a majority of the directors then in office, although less than a
quorum, or by a sole remaining director. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Cumulative Voting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless our certificate of incorporation
provides otherwise. Our certificate of incorporation prohibits cumulative voting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limits on Written Consents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DGCL permits stockholder action by written consent unless otherwise provided by our certificate of incorporation. Our certificate of incorporation
precludes stockholder action by written consent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholder Meetings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and our <FONT STYLE="white-space:nowrap">by-laws</FONT> provide that special meetings of stockholders may be called only by or
at the direction of the board of directors, the chairman of the board of directors or the chief executive officer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment of Certificate of
Incorporation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The affirmative vote of holders of at least a majority of the voting power of our outstanding shares of stock will generally be required
to amend provisions of our certificate of incorporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment of <FONT STYLE="white-space:nowrap">By-laws</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">by-laws</FONT> may generally be altered, amended or repealed, and new <FONT STYLE="white-space:nowrap">by-laws</FONT> may
be adopted, by the affirmative vote of either a majority of directors present at any regular or special meeting of the board of directors called for that purpose or by the affirmative vote of the holders of at least a majority of the voting power of
the outstanding shares of stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Limitations on Stockholder Actions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">by-laws</FONT> also impose some procedural requirements on stockholders who wish to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make nominations in the election of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">propose that a director be removed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">propose any repeal or change in our <FONT STYLE="white-space:nowrap">by-laws;</FONT> or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">propose any other business to be brought before an annual meeting of stockholders. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under these procedural requirements, in order to bring a proposal before a meeting of stockholders, a stockholder must deliver timely notice of a proposal
pertaining to a proper subject for presentation at the meeting to our corporate secretary along with the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a description of the business or nomination to be brought before the meeting and the reasons for conducting such
business at the meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the stockholder&#146;s name and address; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any material interest of the stockholder in the proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares beneficially owned by the stockholder and evidence of such ownership; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the names and addresses of all persons with whom the stockholder is acting in concert and a description of all
arrangements and understandings with those persons, and the number of shares such persons beneficially own. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To be timely, a stockholder
must generally deliver notice: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in connection with an annual meeting of stockholders, not less than 120 nor more than 150 days prior to the month
and day corresponding to the date on which the annual meeting of stockholders was held in the immediately preceding year, but in the event that the date of the annual meeting is more than 30 days before or more than 30 days after the anniversary
date of the preceding annual meeting of stockholders, a stockholder notice will be timely if received by us not later than the close of business on the 10th day following the day on which we first publicly announce the date of the annual meeting; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in connection with the election of a director at a special meeting of stockholders, not less than 40 nor more
than 60 days prior to the date of the special meeting, but in the event that less than 50 days&#146; notice or prior public disclosure of the date of the special meeting of the stockholders is given or made to the stockholders, a stockholder notice
will be timely if received by us not later than the close of business on the 10th day following the day on which a notice of the date of the special meeting was mailed to the stockholders or the public disclosure of that date was made.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to submit a nomination for our board of directors, a stockholder must also submit any information with respect to the nominee
that we would be required to include in a proxy statement, as well as certain other information. If a stockholder fails to follow the required procedures, the stockholder&#146;s proposal or nominee will be ineligible and will not be voted on by our
stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Opportunity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and the stockholders agreement provide that each of TPG Global, LLC (&#147;TPG&#148;), The Advisory Board and UPMC and their
respective affiliates will not have any duty to refrain from (i)&nbsp;engaging, directly or indirectly, in the same or similar business activities or lines of business as us, including those business activities or lines of business deemed to be
competing with us, or (ii)&nbsp;doing business with any of our clients, customers or vendors. In the event that TPG, The Advisory Board or UPMC or any of their respective affiliates acquires knowledge of a potential business opportunity which may be
a corporate opportunity for us, they will have no duty to communicate or offer such corporate opportunity to us. Our certificate of incorporation and the stockholders agreement also provide that, to the fullest extent permitted by law, none of such
stockholders or their respective affiliates will be liable to us, for breach of any fiduciary duty or otherwise, by reason of the fact that any such stockholder or any of its affiliates directs such corporate opportunity to another person, or
otherwise does not communicate information regarding such corporate opportunity to us, and we will waive and renounce any claim that such business opportunity constituted a corporate opportunity that should have been presented to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation of Liability of Directors and Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
certificate of incorporation provides that no director will be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director, except as required by applicable law, as in effect from time to time.
Currently, Delaware law requires that liability be imposed for the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to our company or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or which involved intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of
the DGCL; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, neither we nor our stockholders have the right, through stockholders&#146; derivative suits on our behalf, to recover monetary damages against a
director for breach of fiduciary duty as a director, including breaches resulting from grossly negligent behavior, except in the situations described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">by-laws</FONT> provide that, to the fullest extent permitted by law, we will indemnify any officer or director of our
company against all damages, claims and liabilities arising out of the fact that the person is or was our director or officer, or served any other enterprise at our request as a director, officer, employee, agent or fiduciary. We will reimburse the
expenses, including attorneys&#146; fees, incurred by a person indemnified by this provision when we receive an undertaking to repay such amounts if it is ultimately determined that the person is not entitled to be indemnified by us. Amending these
provisions will not reduce our indemnification obligations relating to actions taken before an amendment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forum Selection </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation requires, to the fullest extent permitted by law, that derivative actions brought on our behalf, any action asserting a claim
of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders and other similar actions, may be brought only in specified courts in the State of Delaware. Although we believe this provision
benefits us by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies, the provision may have the effect of discouraging lawsuits against our directors and officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-takeover Effects of Some Provisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some provisions of our certificate of incorporation and <FONT STYLE="white-space:nowrap">by-laws</FONT> could make the following more difficult: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquisitions of control of us by means of a proxy contest or otherwise; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">removal of our incumbent officers and directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions, as well as our ability to issue preferred stock, are designed to discourage coercive takeover practices and inadequate takeover bids. These
provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection give us the potential ability to negotiate with the proponent of
an unfriendly or unsolicited proposal to acquire or restructure us, and that the benefits of this increased protection outweigh the disadvantages of discouraging those proposals, because negotiation of those proposals could result in an improvement
of their terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delaware Business Combination Statute </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have elected in our certificate of incorporation not to be subject to Section&nbsp;203 of the DGCL, an antitakeover law. In general, Section&nbsp;203
prohibits a publicly held Delaware corporation from engaging in a business combination, such as a merger, with a person or group owning 15% or more of the corporation&#146;s voting stock for a period of three years following the date the person
became an interested stockholder, unless (with certain exceptions) the business combination or the transaction in which the person became an interested stockholder is approved in a prescribed manner. Accordingly, we will not be subject to any
anti-takeover effects of Section&nbsp;203. Nevertheless, our certificate of incorporation contains provisions that have the same effect as Section&nbsp;203, except that they provide that each of TPG, UPMC and The Advisory Board and their transferees
will not be deemed to be &#147;interested stockholders,&#148; regardless of the percentage of our voting stock owned by them, and accordingly will not be subject to such restrictions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and
registrar for the Class&nbsp;A common stock is American Stock Transfer&nbsp;&amp; Trust Company, LLC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Class&nbsp;A common stock is listed on the NYSE under the symbol &#147;EVH&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx386518_10"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders will act independently of the Company in making their respective decisions with respect to the timing, manner and size of each and
any sale. Subject to the terms and restrictions set forth under applicable law, the selling stockholders may, from time to time, offer and sell, separately or together, any or all of the shares of our Class&nbsp;A common stock beneficially owned by
them covered by this prospectus. The shares of our Class&nbsp;A common stock may be sold in one or more transactions at fixed prices or prices subject to change, at prices related to prevailing market prices at the time of sale, at varying prices
determined at the time of sale, or at negotiated prices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may use any one or more of the following methods when selling shares:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through underwriters, brokers or dealers or agents for resale to the public or to institutional investors at
various times; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in one or more underwritten offerings on a firm commitment or best efforts basis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through negotiated transactions, including, but not limited to, block trades in which the broker or dealer so
engaged will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through brokers or dealers, who may act as agents or principals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on any national securities exchange or quotation service on which the shares may be listed or quoted at the time
of sale at market prices prevailing at the time of sale, at prices related to such prevailing market prices, or at negotiated prices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT>
market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in private transactions other than exchange or quotation service transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through short sales, purchases or sales of put, call or other types of options, forward delivery contracts,
swaps, offerings of structured equity-linked securities or other derivative transactions or securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether or not the options are listed
on an options exchange; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through offerings of securities exercisable, convertible or exchangeable for shares, including, without
limitation, securities issued by trusts, investment companies or other entities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through offerings directly to one or more purchasers, including institutional investors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through distributions or transfers to their respective members, partners or shareholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through ordinary brokerage transactions and transactions in which a broker solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in &#147;at the market&#148; offerings as defined in Rule 415 under the Securities Act, at negotiated prices, at
prices prevailing at the time of sale or at prices related to such prevailing market prices, including sales made directly on a national securities exchange or sales made through a market maker other than on an exchange or other similar offerings
through sales agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through a combination of any such methods of sale; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through any other method permitted under applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent required by applicable law or regulation, the number of shares our Class&nbsp;A common stock to be sold, the names of the selling stockholders,
the respective purchase prices and public offering prices, the names of any underwriter, agent or dealer and any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying supplement to this
prospectus or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may also sell shares of our Class&nbsp;A common stock under Rule 144 or any other
exemption from registration under the Securities Act, in each case if available, rather than under this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may, from
time to time, pledge or grant a security interest in some or all of the shares owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares, from time to time,
under this prospectus or under an amendment or supplement to this prospectus amending the list of selling stockholders to include the pledgees, transferees or other successors in interest as selling stockholders under this prospectus. The selling
stockholders also may transfer the shares in other circumstances, in which case the pledgees, assignees, permitted transferees, donees or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT>
will be the selling beneficial owners for purposes of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A selling stockholder that is an entity may elect to make an <FONT
STYLE="white-space:nowrap">in-kind</FONT> distribution of the securities to its members, partners or shareholders pursuant to the registration statement of which this prospectus is a part by delivering a prospectus. To the extent that such members,
partners or shareholders are not affiliates of ours, such members, partners or shareholders would thereby receive freely tradable securities pursuant to the distribution through a registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the sale of the registrable securities, the selling stockholders may enter into hedging transactions with broker-dealers or other financial
institutions, which may in turn engage in short sales of shares of our Class&nbsp;A common stock in the course of hedging the positions they assume. The selling stockholders may also sell shares of our Class&nbsp;A common stock short and deliver
these securities to close out their short positions, or loan or pledge shares of our Class&nbsp;A common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions with
broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares of our Class&nbsp;A common stock offered by this prospectus, which
shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate proceeds to the selling stockholders from the sale of the registrable securities offered by them will be the purchase price of the shares of our
Class&nbsp;A common stock less discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of shares of our
Class&nbsp;A common stock to be made directly or through agents. Each selling stockholder may be deemed to be a statutory underwriter under the Securities Act. In addition, any broker-dealers who act in connection with the sale of the registrable
securities may be deemed to be &#147;underwriters&#148; within the meaning of Section&nbsp;2(11) of the Securities Act, and any commissions received by them and profit on any resale of the registrable securities as principal may be deemed to be
underwriting discounts and commissions under the Securities Act. Broker-dealers engaged by the selling stockholders may arrange for other broker-dealers to participate in sales. Such broker-dealers and any other participating broker-dealers may, in
connection with such sales, be deemed to be underwriters within the meaning of the Securities Act. If the selling stockholders effect such transactions through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may
receive commissions in the form of discounts, concessions or commissions from the selling stockholders or commissions from purchasers of the registrable securities for whom they may act as agent or to whom they may sell as principal, or both (which
discounts, concessions or commissions as to particular underwriters, broker-dealers or agents may be less than or in excess of those customary in the types of transactions involved). Any discounts or commissions received by any such broker-dealers
may be deemed to be underwriting discounts and commissions under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Underwriters, brokers, dealers and agents may be customers of,
engage in transactions with, or perform services for, us and our subsidiaries in the ordinary course of business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Underwriters, brokers, dealers and agents may from time to time purchase and sell securities in the
secondary market, but are not obligated to do so, and there can be no assurance that there will be a secondary market for the securities or liquidity in the secondary market if one develops. From time to time, underwriters and agents may make a
market in the securities but are not obligated to do so and may cease to do so at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurances that the selling stockholders will
sell, nor are the selling stockholders required to sell, any or all of the shares of our Class&nbsp;A common stock offered under this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx386518_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the prospectus supplement, certain legal matters regarding the validity of the Class&nbsp;A common stock offered hereby will be
passed upon for us by King&nbsp;&amp; Spalding LLP. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx386518_12"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of Evolent Health, Inc. as of December&nbsp;31, 2021 and 2020, and for each of the three years in the period ended December&nbsp;31,
2021, incorporated by reference in this Prospectus by reference to Evolent Health, Inc.&#146;s annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, and the effectiveness of Evolent Health,
Inc.&#146;s internal control over financial reporting have been audited by Deloitte&nbsp;&amp; Touche LLP, an independent registered public accounting firm, as stated in their reports. Such financial statements are incorporated by reference in
reliance upon the reports of such firm given their authority as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;14. </B><B><I>Other Expenses of Issuance and Distribution</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table itemizes the expenses incurred by us in connection with the issuance and registration of the shares of our Class&nbsp;A common stock being
registered hereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC Registration Fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and Duplicating Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">**</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting Fees and Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">**</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal Fees and Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">**</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous Fees and Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">**</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">**</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(*)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Applicable SEC registration fees have been deferred in accordance with Rules 456(b) and 457(r) of the
Securities Act and will be paid at the time of any particular offering under this registration statement and are therefore not estimable at this time. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(**)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These fees and expenses are incurred in connection with the issuance of shares and will vary based on the
number of shares offered and number of issuances and, accordingly, are not estimable at this time. An estimate of the aggregate fees and expenses in connection with the issuance and distribution of the shares being offered will be included in the
applicable prospectus supplement. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;15. </B><B><I>Indemnification of Directors and Officers</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the DGCL provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses
(including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any threatened, pending or completed actions, suits or proceedings in which such person is made a
party by reason of such person being or having been a director, officer, employee or agent to the registrant. The DGCL provides that Section&nbsp;145 is not exclusive of other rights to which those seeking indemnification may be entitled under any
bylaw, agreement, vote of stockholders or disinterested directors or otherwise. Our certificate of incorporation provides for indemnification by Evolent Health, Inc. of its directors, officers and employees to the fullest extent permitted by the
DGCL. Section&nbsp;145 further authorizes a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a
director, officer, employee or agent of another corporation or enterprise, against any liability asserted against him and incurred by him in any such capacity, or arising out of his status as such, whether or not the corporation would otherwise have
the power to indemnify him under Section&nbsp;145. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;102(b)(7) of the DGCL permits a corporation to provide in its certificate of
incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i)&nbsp;for any breach of the
director&#146;s duty of loyalty to the corporation or its stockholders, (ii)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&nbsp;for unlawful payments of dividends or
unlawful stock repurchases, redemptions or other distributions, or (iv)&nbsp;for any transaction from which the director derived an improper personal benefit. Our certificate of incorporation provides for such limitation of liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain standard policies of insurance under which coverage is provided (i)&nbsp;to our directors and officers against loss arising from claims made by
reason of breach of duty or other wrongful act, and (ii)&nbsp;to Evolent Health, Inc. with respect to payments which may be made by us to such officers and directors pursuant to the above indemnification provision or otherwise as a matter of law.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into customary indemnification agreements with each of our directors and officers. The
indemnification agreements provide the executive officers and directors with contractual rights to indemnification and expense reimbursement, to the fullest extent permitted under the DGCL. Our indemnification agreements also require us to advance
expenses to our directors and officers as incurred in connection with legal proceedings against them for which they may be indemnified and that the rights conferred in the indemnification agreements are not exclusive. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16. </B><B><I>Exhibits</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following exhibits are filed as part of, or incorporated by reference into, this registration statement on Form <FONT STYLE="white-space:nowrap">S-3:</FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Exhibit&nbsp;No.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Description</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1628908/000162890816000054/exhibit31.htm">Amended and Restated Certificate of Incorporation of Evolent Health, Inc. (incorporated by reference to Exhibit 3.1 to our Current Report on Form
 <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on June<U></U>&nbsp;15, 2016). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000066/a20210610exhibit31.htm">Certificate of Amendment of the Second Amended and Restated Certificate of Incorporation of Evolent Health, Inc., dated June<U></U>&nbsp;10,
 2021, (incorporated by reference to Exhibit 3.1 to our Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on June<U></U>&nbsp;10, 2021). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1628908/000162890820000143/a20201214form8-kex31.htm">Third Amended and Restated <FONT STYLE="white-space:nowrap">By-laws</FONT> of Evolent Health, Inc. (incorporated by reference to Exhibit
 3.1 to our Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on December<U></U>&nbsp;14, 2020). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1628908/000119312515190849/d838828dex41.htm">Form of Class<U></U>&nbsp;
A common stock certificate (incorporated by reference to Exhibit 4.1 to our Registration Statement (Amendment No.<U></U>&nbsp;1) on Form <FONT STYLE="white-space:nowrap">S-1/A</FONT> (Registration No.<U></U><FONT STYLE="white-space:nowrap">&nbsp;
333-203852)</FONT> filed with the SEC on May<U></U>&nbsp;18, 2015). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex41.htm">Registration Rights Agreement, dated as of June<U></U>&nbsp;
4, 2015, by and among Evolent Health, Inc., TPG Growth II BDH, L.P., TPG Eagle Holdings, L.P., UPMC, The Advisory Board Company and Ptolemy Capital, LLC (incorporated by reference to Exhibit 4.1 to our Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on June<U></U>&nbsp;10, 2015). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1628908/000162890822000098/evh-20220630.htm">Registration Rights Agreement, dated August&nbsp;
1, 2022, by and between Evolent Health, Inc., TPG Growth V Iceman, L.P., and the individuals set forth on Schedule I thereto (incorporated by reference to Exhibit 4.1 to our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with
 the SEC on August&nbsp;3, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d386518dex51.htm">Opinion of King&nbsp;&amp; Spalding LLP. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d386518dex231.htm">Consent of Deloitte&nbsp;&amp; Touche LLP. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d386518dex51.htm">Consent of King&nbsp;&amp; Spalding LLP (included as part of Exhibit 5.1). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#sig">Power of Attorney (included on signature pages). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d386518dexfilingfees.htm">Filing Fee Table. </A></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed, if necessary, by amendment or incorporated by reference in connection with the offering of shares
of Class&nbsp;A common stock. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item 17. </B><B><I>Undertakings</I></B><B>&nbsp; </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To file, during any period in which offers or sales are being made, a post-effective amendment to this
registration statement: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to reflect in the prospectus any facts or events arising after the effective date of the registration statement
(or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in
volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus
filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#147;Calculation of Registration Fee&#148; table in the
effective registration statement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to include any material information with respect to the plan of distribution not previously disclosed in the
registration statement or any material change to such information in the registration statement; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided, however,</I> that
paragraphs (i),(ii) and (iii)&nbsp;above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to
Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment
shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To remove from registration by means of a post-effective amendment any of the securities being registered which
remain unsold at the termination of the offering. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining liability under the Securities Act to any purchaser:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the
registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration
statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x)&nbsp;for the purpose of providing the information required by Section&nbsp;10(a) of the Securities Act shall be deemed to be part of and
included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule
430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that
prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; <I>provided, however,</I> that no statement made in a registration statement or prospectus that is part of the
registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the
registration statement or made in any such document immediately prior to such effective date; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in
the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the
securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such
securities to such purchaser: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be
filed pursuant to Rule 424; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or
used or referred to by the undersigned registrant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The portion of any other free writing prospectus relating to the offering containing material information about
the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The undersigned registrant hereby undertakes that, for purposes of determining any liability under the
Securities Act of 1933, each filing of the registrant&#146;s annual report pursuant to Section&nbsp;13(a) or Section&nbsp;15(d) of the Securities Exchange Act of 1934 (and where applicable, each filing of an employee benefit plan&#146;s annual
report pursuant to Section&nbsp;15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for
liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such
indemnification is against public policy as expressed in the Exchange Act of 1934 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the
registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that the registrant
meets all of the requirements for filing on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Arlington, State of
Virginia, on this 3<SUP STYLE="font-size:75%; vertical-align:top">rd</SUP> day of August, 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>EVOLENT HEALTH, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By: /s/ John Johnson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Johnson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each person whose signature appears below hereby constitutes and appoints John Johnson and Jonathan Weinberg and each of them singly, his or her true and
lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agents, with full power of substitution and <FONT STYLE="white-space:nowrap">re-substitution,</FONT> for him or her and in his or her name,
place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto and all other documents in connection therewith, with
the Securities and Exchange Commission, granting unto each said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents full power and authority to do and perform each and every act and thing
requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents or either of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities
indicated and on the 3<SUP STYLE="font-size:75%; vertical-align:top">rd</SUP> day of August, 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="51%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Seth Blackley</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Seth Blackley</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Executive Officer and Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Principal Executive Officer)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ John Johnson</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">John Johnson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Principal Financial Officer)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Aammaad Shams</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Aammaad Shams</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Accounting Officer and Controller</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Principal Accounting Officer)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Craig Barbarosh</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Craig Barbarosh</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ M. Bridget Duffy</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">M. Bridget Duffy, MD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ David Farner</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">David Farner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Peter Grua</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Peter Grua</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="51%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Diane Holder</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Diane Holder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Kim Keck</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Kim Keck</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Cheryl Scott</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cheryl Scott</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Tunde Sotunde</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Tunde Sotunde</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Frank Williams</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Frank Williams</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d386518dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g386518dsp29.jpg" ALT="LOGO">
</P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">King&nbsp;&amp; Spalding LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">1185 Avenue of
the Americas</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">34th Floor</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">New York, NY 10036-2601</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">www.kslaw.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;3, 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evolent
Health, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">800 N. Glebe Road, Suite 500 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arlington,
Virginia 22203 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as
counsel to Evolent Health, Inc., a Delaware corporation (the &#147;Corporation&#148;), in connection with the preparation and filing of a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3ASR</FONT> (the &#147;Registration
Statement&#148;) with the Securities and Exchange Commission (the &#147;Commission&#148;) under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). The Registration Statement relates to the registration under the Securities Act
of the offer and sale, from time to time pursuant to Rule 415 under the Securities Act, of the Corporation&#146;s Class&nbsp;A common stock, par value $0.01 per share (&#147;Common Stock&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In acting so we have examined and relied upon the accuracy of original, certified, conformed or photographic copies of such records, agreements, certificates
and other documents as we have deemed necessary or appropriate to enable us to render the opinions set forth below. In all such examinations, we have assumed the genuineness of signatures on original documents and the conformity to such original
documents of all documents submitted to us as certified, conformed or photographic copies and, as to certificates of public officials, we have assumed the same to have been properly given and to be accurate. As to matters of fact material to this
opinion, we have relied, without independent verification, upon certificates, statements and representations of public officials and representatives of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the foregoing, and subject to the additional assumptions, qualifications and limitations set forth below, we are of the opinion that any shares of
Common Stock, when (i)&nbsp;the terms of their issuance and sale, and all related matters, have been duly authorized and established by all necessary corporate action and (ii)&nbsp;such shares of Common Stock have been duly delivered to the
purchasers thereof upon the payment of the consideration therefor (which consideration is not less than the par value of the Common Stock), will be duly authorized, validly issued, fully paid and
<FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is limited in all respects to the federal laws of the United States of America and
the General Corporation Law of the State of Delaware, and no opinion is expressed with respect to the laws of any other jurisdiction or any effect that such laws may have on the opinions expressed herein. This opinion is limited to the matters
stated herein, and no opinion is implied or may be inferred beyond the matters expressly stated herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is given as of the date hereof, and
we assume no obligation to advise you after the date hereof of facts or circumstances that come to our attention or changes in law that occur, which could affect the opinions contained herein. This opinion is being rendered for the benefit of the
Corporation in connection with the matters addressed herein. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evolent Health, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;3, 2022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference to us under the caption &#147;Legal Matters&#148; in
the prospectus that forms a part thereof. In giving such consent, we do not admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ King&nbsp;&amp; Spalding LLP </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d386518dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONSENT&nbsp;OF&nbsp;INDEPENDENT&nbsp;REGISTERED&nbsp;PUBLIC ACCOUNTING&nbsp;FIRM</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the incorporation by reference in this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> of our reports dated
February&nbsp;23,&nbsp;2022 relating to the financial statements of Evolent Health, Inc. and the effectiveness of Evolent Health, Inc.&#146;s internal control over financial reporting, appearing in the Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> of Evolent Health, Inc. for the year ended December&nbsp;31,&nbsp;2021. We also consent to the reference to us under the heading &#147;Experts&#148; in such Registration Statement.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Deloitte&nbsp;&amp;&nbsp;Touche&nbsp;LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">McLean,&nbsp;Virginia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">August&nbsp;3,&nbsp;2022</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>d386518dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Table </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT STYLE="white-space:nowrap">S-3ASR</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Evolent Health,
Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Newly Registered Securities </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Security<BR>Type</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Security<BR>Class<BR>Title</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Fee<BR>Calculation<BR>or Carry<BR>Forward<BR>Rule</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Amount<BR>Registered</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Proposed<BR>Maximum<BR>Offering<BR>Price Per<BR>Share</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Maximum<BR>Aggregate<BR>Offering<BR>Price</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Fee<BR>Rate</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Amount of<BR>Registration<BR>Fee</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Carry<BR>Forward<BR>Form<BR>Type</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Carry<BR>Forward<BR>File<BR>Number</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Carry<BR>Forward<BR>Initial<BR>Effective<BR>Date</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">Filing Fee<BR>Previously<BR>Paid In<BR>Connection<BR>with<BR>Unsold<BR>Securities<BR>to be<BR>Carried<BR>Forward</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="25" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="25" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt">Newly Registered Securities</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fees to Be</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Class&nbsp;A common stock,&nbsp;par value $0.01 per share(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Rule 456(b) and Rule 457(r)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fees</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Previously</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="25" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="25" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt">Carry Forward Securities</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Carry</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Forward</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Securities</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">N/A</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="right" STYLE="padding-bottom:1pt ;">Total Offering Amounts&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="right" STYLE="padding-bottom:1pt ;">Total&nbsp;Fees&nbsp;Previously&nbsp;Paid&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="right" STYLE="padding-bottom:1pt ;">Total Fee Offsets&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="right" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">Net Fee Due&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An indeterminate number of shares of Class&nbsp;A common stock of the registrant may be sold from time to time
in unspecified numbers and at indeterminate prices. The proposed maximum offering price per security and aggregate offering price will be determined from time to time in connection with issuances of securities registered under this registration
statement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Rules 456(b) and 457(r) under the Securities Act, the Registrant is deferring payment of the entire
registration fee. Any registration fee will be paid subsequently on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pay-as-you-go</FONT></FONT></FONT> basis in accordance with Rule 457(r).
</P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g386518dsp29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g386518dsp29.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MC0S@ ?P*S,'/MD'ZT :/AW5)-;\.:=JDL'V>2Z@65HO[A(SB@#3H * "@ H
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M21C>2R@<=ASS0 WXG2W&H_#O4]'M+#4+O49XHU5(;.5@3N5C\P7;T![T 6?
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E "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g386518g03s13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g386518g03s13.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1CJ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &,Z^8U X0DE-! 0       \< 5H  QLE1QP"   "!%H .$))300E
M   051]O(Q]&.M6$IZ!E"H!?%3A"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!C=2;@
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              (P   (V          $
M                 0             "-@   (P
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   (P     4F=H=&QO;F<   (V
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   ",     %)G:'1L;VYG   "-@    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     3A"24T$#      .9P
M  $   "@    *    >   $L    .2P 8  '_V/_M  Q!9&]B95]#30 "_^X
M#D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3
M&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0
M#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,_\  $0@ * "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $%
M 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$          0 "
M P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&
M%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B
M9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>G
MM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"
M(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$
MP]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:
M  P# 0 "$0,1 #\ ],S^HX'3:/M.?D5XM,QZEK@P$\[&[OI/T^@JG3?K/]7^
MJV^CT_/ION[5!VUY U)959ML?_9:O+?K!U"GK?URN'6,IV)TW%OLQFV,:7FN
MJDNK=Z-;&V?ILNVO^=]-^SU/]'1Z:K?6*CZKX]F-D?5CJ%UKVNE['BUME3V^
M^G*Q[[:J?SV^[W_3]/TU., H D\4A>@] \T6^O7_ %BZ%CYW[/OSZ*LP.:S[
M.]X#]SPTU-V'_2>HS:K>7EXV%CORLNUE&/4)LML(:UHX]SG+R3ZY5V]2Z5T;
MZT1MLSZ!C9CV@- R*MQKM&W]_9D_]LTK6^NWUI'4/J=TEK719U4"[* T &-'
MVAG_ +'^G_VTA[-\%'YCPR_JD*O=[[IW6>E=4%AZ=E598I@6&IP=M+IV[MO[
MVU4;_KI]5*+_ $+.J8_J P=K]S0?Y5E>ZMG]IZ\ZZO;E=!^I_3>CUN--G6&V
M9_4B)#BPBMM6+_):ZIU5>1_X7]/^;ML6UT;_ !7865T6G(S<JZK-R:A:QM.P
M55;V[ZJW5O8YUNS=^F_2,W_X/TTO;@!Q2D>$DB->'55E]"Q\C'RJ6WXUK+Z;
M!++:W!['#^2]DM<O*_JMEY;_ /&+Z3\BY]7VK.'I
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M! ,! 0$             !08'" $#! ()"O_$ % 1  $# @0#!04%! 4(!PD
M  $" Q$$(0 %$C$&05$'$R)A<0@4,H&1(T*AL? 54L'1%B0S-/$))4-38G.R
MX1<V56-D<G0F5(*#DI.BM-+_V@ , P$  A$#$0 _ '^.#!@X,&#@P8.#!@X,
M&#@D;3?I@P<8D=1@P<9P8.#!@X,&#@D'8S@P<&#!P8,'!@P<&#"GWQ.&J74E
MILDM%!-/V=,IX83N3/42I;28UND[40LAJZM@\(,TT6%>LPD?LDLW,!'BY\3R
MOVF]!+I\RJ!Y5[+\IRW-'\V&84-+6=RU3*;]YIVZC0"I[4$=X"$ZH$@?%SVP
MBYP\\REM3;ZF09LF;D$'T_,[8HPY=7,5UY9$UYZ0Z/>=86HNW4RV9[H$'9ZK
M8<KW"4@Y^&?3#=!Y%RT8ZE56KY@[3.*;AJX1415((E4(8OH_^-.&>'Z7AO,:
MRDRG+Z=YAE3B'&*-EEP*3I  6V-0$JN!91 ]<)])45+C[*55*UH4L)*5$P;@
M<_G$V,]1C9&$$=MQW[^@=^P;[?A]=OEQ6D'F9A6F!TD?K^6'41!C?TN/K\_U
M&.3CU@P<&#!P8,'!@P<&#!P8,'&)'48,'&<&#@P8XU1$$Q$NVX;"'?;?N _7
MV^0"/RX\K/A,0;6DF)]0%&WD#M@MS_7Y8H&S_P#$7:*--^;,J8%O- U$R%RQ
M'=9JB69]6ZA27L YF()?R[M:'>/\BQCUTQ,H'ZE9RP9K*% !.W3$=@?.4=G>
M>YQEK&94JZ,-5"=20M]T*$6-NYTQ-K&9D&",)SN9,,N*;4%E2"4G2B;R>A-H
M\AOB8W+QYJ6G_F4.<J-<&UK*E>/A]M3%[,;)4%784KPMY-9B1'V0,#:K-Y@R
M)JK)"^\T#+P@5:>""_6H"*-G_"^:<,JHD9DMA1JFUK0IET.:@@)"M9  "@5"
M4B8O!(QT4U4W5 J;"A$3( @F\?(;[1/ULW]>$ $1(@#ERQTX.,X,'!@P<8D7
MN+;^7K@QZF.0I1,8Q0*7U$1#8/3U_:'[0X"I($D@#J2(^N#&!\F:F\$8A%5.
M_P"2ZQ!/4@$QHP7*DC+AL(EV^RHI%[( ;J 0[MRAMW$0 !'AL9EQ;PWE1<%7
MFE$AQLJ#C:7.]=2I)\04VT%J!!!$1,GEL>1^NHZ4*-0^AL)^(3*QY:4RH$\C
M'3D9Q#JR\V?27!*'2;R]VGBAOU*1%.DTB["(B'0>6/%BH B " D*81 =NG<!
M'A)H^TK@VMJ$4J<V2SK.@O/4E7W(5<0=-.I46!U:=(D7WAJYMQWD65-*=4:N
MK"1K**9HE<2=@M3<CPDP"?2\8X*YS=M%<VX2:25\L=2,;I PV6E6-!)(YC 7
M95S',9)N4 $?O'*H=,H"(BH.P[3%E'".9<0TZ:CA][+LW:TEP"CS*B;>4@1<
M4KS[-01=(CNID@&YQ'"_:2[+:5Y-/FN:9CDZU.):_P XY!G/=!Q1,(-2S1O,
M7TJ,]YI(2?%:\[,:YQQ'E^-+*XRR+5KHR( "L:"E&[I9#<"]G++<CUL/W@_V
MANF(COMZ#LFYCDF;Y2H)S++JVAN0%/LK0VLI-PERZ%^J5'S.V)8R'B[ACB9K
MO>'\]RO-DZ$N*%'5-N.MI5$%Q@'O6R9@!Q"2=HD8RN51,W]4Y1[;[ 8-]OGM
MZ[=_7A,D3$B>G/#CD'Z3\L>^X=NX=_3Z_A\^,XS@ 0'T$!V'8=O8?E^/!@P<
M&#!Q@D#<@>N#!P'Y?/\ 5O6_I@Q@3.VI_3[IEKGZ69]S!0\30)Q5*T=W*P-(
MM>341*!E4(>+$QY:;<D 0ZFT0R>N $2AX8"8..FCH:S,G0Q14KU0ZHPE+;:E
M7)@21 N?,#>]L:UN-M@J6M*1YD V'3G\O2-IK"=?$.\J9M-GA0U"RSDI5O!"
M9:XCRVM!F^\4OC%??H84PM_O;^*"&VQ3#MV#=S#@7B=3>O\ 9RQ-@DZM<GJ@
M#Z0HSR..7]HTNK2'!/X<^=[VF(ZXL3T[ZUM*VK*.5D-.N=<?95,U;F=/XFN3
M1"66,:E5(@9S+U*428V>);E6422%:1B6J8G62 IS>*EUMVORO,<L4EO,**II
M%'8+;4$D21.J"(,3OMUOCI;?:=LVXE1O8&]A)M^AYXS]<;C6L?U*RWJXRR,'
M4Z?!2EELLTY(X6;0\%",U9"5DG)&B+AT9NQ9(+.5_!054!)(YBIFVV'C;;4M
M:6VTK4MPA*$)$DJ)(2!/WE6$$[D",;"0!)V&*Z0YS_*Y'O\ STL/;?/SD^._
M<0[#]A;>PB'?80_+=;/#/$(*9RBK3J$I*FB)!_=)@<^O/&@U=,-WD#YG^6)J
MX)U"X7U-4-KD_ V1*YE#'[R3E(=K::NX6<1RDI"N19RK$WF4&SA)RR< )%4U
M42&$IB*D Z:A#F2:JDJ:%_W6L86P\D:BA8@IF2";D7Z28O\ +:AQ#@U(4%"8
MD?K\[XS1QJQ[Q"3.7,<T1:9[VKC+/6I''.,;\A$QTVM5+"\DBRK>)EO&&,>N
M$F4:\(@F]*W5.W(JH14Z12J^'X2B1U%*AR/.<Q9-519;65%*"I/>-L**=0,*
M$[6,CG&V-*WVF82ZZE*CU.XF!$?K;'P88YENA?41D*+Q9A'4GC[)>0YIK)O8
MNJ5D\VO)O&4,R4D)5T4'$.W;IH,6:1UG"JZZ1"AX9"B911,A\5V19SES/O=;
ME=93L2$I<<;4E)FPL1 )]1/*9$C=0RZK0VXE2P)*1,C]?SZ8G*HJ5(H&-N(#
M^'^ ?A[>_KPE3IOI4>9M,3&P D^<"T8W?AB &H;FG:!-+<D]@,RZF\<P5KCS
MK)/:;".Y"\6YDX0 /$:2%>H["PR<4Z P] )2S=B(J=1-P,0X N9?P_G>:I#E
M#E[[K1_TA;4E(-[$GSZ G'.[5,-3K<2".4R?PG;ZXBW4_B#N5-;)9.()J/<5
MQ14_AIOK?B[*E>B1.(@  :2=4\S9 HB/95R=!$  3'4*4HB"J[P-Q.T@K.6N
MJ"1)2@$J(&\ A(L 3!,] >>H5],HQW@_6WR/(_H6LXLS3B;.-7:W;#N1J9D^
MI/!$B%AHMCB[-%>*4"B=NJ\B7+E%NZ3 Y!4;+G2<$*8IC)@40$6M4T]32N*:
MJJ=UA8W2XDI5!$@P0-P>OY8ZT+0M.I"PL;2"#^6,G!L(!MW#;^-_K\^-0V$7
M'Z_0\L>L)B?%N_VMH#_[OU1_A_KM/G\#^7$T=C_]XSO_ '%)_P ;WD?US&X0
ML[^!D]%C_B3/\,+N\K<-^8]HA#M_UD<:>OO_ ,/->P?M_P!X>\C<>?\ 53-Q
M,Q3D>D*1;\(F+DQSG"70_P!Z9\WT_G^OG&-JZ'H'X!]?;BIY^(7_ 'OEX1_C
MAXX_ LUGKU.AI"Q6J;BJW7HAHO(2T[.2#6)B(MBV+UKO)&3?*HLV31 @]:SA
MRLFDF7N8X!WX]!*W5H:0A;BU$ !M)49-@( )N381Z8P5)2"5*"0.MO7Z8J9R
M=SY^5IBR96@9/4Y$VN1:N%6SHV-Z=?<@1B"B)^@^TY6:R_@W9=P'91A(ND=B
MF'Q.W=U4W!7$M0A*TY8\A*DA2"X"DJ24RDV"MQ$S!',6QQKS"F08[P*@P2#8
M7 _C];;XRQ@'G <N?4K-Q]7QAJ@HAK;+*%0C*G=$IS&\_(N5%/#1:1S2^Q5>
M1DWBYQ*5!E&N';I8Q@!-(VX"/%F'#.>96E;U9ES[;*0"7@E2DC>QM(CKI D\
M]\;453#D:7$DDP!-]_I/E,\M\64)+$6*!B#U (;[A_5_+Y[^P@'<.^^VW""F
M_B@B;7D*MR*2+;8Z/.U_,8Z5D[)M$PU0;5E')UFC*9C^D1*\[;+5,G6)%P4.
MV,0J[]Z9NDNN""1E" 84T5#?>#8H^VUEEZH>;IZ=I;S[J@AII"5*6XL[)2!N
M2)@"?E%_*E)0DJ40E($DFP \\5_!SG>5UL&^M3#FX]_]LL !M^<%V_/]G"VG
MA;B10D9-7GTIE[_/]>F-'OE+_P"\-?\ UC$N'>JO3M&X2BM2,KF&B0N"IJ!:
M6>)R?-3:$+5)*#D@,,<\9O94&9USR D$C%F1$7SM;9%NV46.1,Z.BAK7*DT2
M*5TU;:]*J5*"MS5)$$02#8[QIYF!(WJ6A*=2E )B9)M$3/TQ6NX^(1Y4K6R#
M6S:CG:P>9%N%@:8IRTM6-NOH,X"7)3!!1J [B+A-$2=!14#<NPBY?Z#\3=T'
M3ECH2M)(1I5KDB2#:)FV\21?'(:^F! [Q%S .H?CTO;U$8M!P?J*PCJ3IS;(
M.!LG4_*E,=&!()RGS"$JDV="F186,FV*)'T-))IJ$.O&2[9D_;@</,-DC;AP
MVJNBK<O=+-72O4RTWTNI(*I)'AD&0-.Z21R%ACI;=;=&IM04-[?2_3'XVH75
M-I^TJ5>)N>H?*5:Q-59R<3K</.6E1ZDQ?SJS%[))QB)F3-X?S)V+!XY*4Q"E
M$C=38W4  )1457F+Q8H:=;[R-FT#43JZ24V',\L#CK;0"G%!(E(^9( ^I('K
MC6"<QO(-+RUKQU9Y*QS8XZW4*\YUO-EJEIB#J*1D_!2<AXS&29'6215,W<I[
MF(*B1#=NX"'<;6\$TS])PQD])4MJ9?:;<+Z%B%)EUQ4*%Q8'IY@Q&&G7+2Y6
M.ELB"0HG>1 B^T[[?G875_#<:R],&D>0U?*ZD\S5##Z5X9820J!K:J]0^WU*
M\ME0TV5CY%@\$_V:68BQ<B<" 7SJ/3OU" ,+M5RK,LQ=RI5#15-0U3(K&U%M
MH'026M,P)N$F(G8CG)4,J?;9%4'5A"4N""L[A,I)'6>>YMO8X</T]Z_]'.JN
MV2U&T\Z@*'EBV0<$>S2T%55I-5ZP@$WS.,/)KE>1S1,K8C]^S:F$%.OQ7"8
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MC='2;)@N6-CQ7$&,%%)"8Q$""<PIALF JOGIB@*Z_4HJ8J1$R)_+_BKCG/\
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MXUFT) S%HF(2KUR.<2\]8I:,@8"):% SN5FI=XC&Q$<V*80*==\^<H-4BF$
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M5?9NH5!$PE1T'[J@DG7I(Q\\Z_*ZW+*ZKR[,:9=-64-06*AAY"D*2MM9;<2
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M#/NNC31"ZO-)^;M/,TD@*V1*#,1U;?JE*/V)>&:82M(GD1,4XD/#6IC%/AV
MP*(HK-U"G26.0T6Y+F3F3YQEV8MJ4DTM0DK@W4TXL(6#=,PDDF2 #!$QA7?0
M'6'6R+J00+QR//&IWFH66KLQ,UJP,'$3.UZ5DX&;C'9/#=QTK$O'$;*,%R=^
MEPS>MW#=8 $Q .F.PG .]PZ9YFKI4.MJ2MIUL*0H7"T+220-KWON+D2;@LHI
M+:G$&9;48)V,&0+3!V(!@B8D&^+A^91S)9#6GI@Y?&+%)95U,8KQ1,R^:4@
MQ?&RK'S3[&L&L] 2$\1X-*JGZ3$4#K**-Z'80,8QC1_P7PK^Q\WSJL<;*6JB
MH'NBCI.FG)[U85%PHN*6F!*=*$F?%;OJJOWEJF1?2V272KG!( 2)/($DD">7
M,8R!\/)I.5U(\P:IWR;BSO,?Z7XI3,DLNJEUQZ]Z;.DXK%T0J80V!VC8W*UP
M;!L.WZ&'$2CUAQK[4,Y709&:%M6EVO=2PI(,*53)!<<4")(*5H:0Y, A?A)D
MQLRIDKJ%*) 0@&(F283'46$3SD@&P$MP<_>@3E\Y5VI%*"0.Y<U M!R))))E
M,H?[!I-]KDQ8'(%*!AZ8V(2>23E01 J+5FNLH;I((\0YP&^BEXKRE;BM"5U(
M3JM!<=26TI,Q\:H2F;3$D86J]*E4KFF)$&#:8/(WY21.^-:&Z1*Z;KMNH !P
MBJB(@/?H.02&V["(=AW#L [AN'<-N+8/(#S:VDJ22XA:3N)!$$ D WFW,\KB
M"T4D*4(TE0DS) \)M\YC\02+8VOW+MU'5/51HST\9BJLHQD3SN-:S%VIJQ,F
M!X&^5J(:0%XKSQJ4YE&3B*LD>_1227$#*L!9/$Q4;ND%5*;YW0.Y7F]?2O-J
M;4*EU2$J!E3:E%25 DP9!GD=^<X>=,\EYE"P9A(!B;$6V]0?G.)L&,!0W-Z>
M_I^_V_+W]M^$LF!T]8_F!^-\=&$$/BA\\4[)FLO%&)JJ_:24AI_Q4[:W99HH
M1;[/M629AA8?T<<*$$R97L96H6OR;A #@9']($DURE5(8A)_[)*&H8RG,*YQ
ME;3=76,J9[Q(!>:9\*UHDD:500)*9GEAN9RZ%+0A-U(TF>2A,E(F).XF+7]<
M0TY ^/Y>^<T_3PM&('<,L?HWS(<^NGU@DQB(:E34219<X!L4%9F?AV1 ,  H
MJZ(F43&.4!7NTVJ;IN%ZM"UI^V<8;01LI05=($"X"I%MN?7FRUI1JV@D@A)!
M401%@3IF)GE>Q\H&+??BVM@E>7_M_P#):H_;MOX^GG< WW[>FP?+W]A8O8__
M 'S-B.;5,?JMTQ^'X''=GGPT_P#O/XC"\?*WV_I'M$F__:5QE_\ W6W^&_$F
M<?B>%LY B>Z$<MG&C'K%QRVGKA,HC%:@]'A^:A^M\-3?%:4B2DM,NF._H-55
MHFHYQL=:EW)#&,DT5O5"?N(LRR8!T@5=6HN$"KG_ *BAR(D$3.=AB3LD?:1Q
M!6LN$)+^6.M(28E2BMLF""2( .JQWMMA;S=/]623L'(/3QI4F3R@3>X,;3MA
M(2HP2-IMU5K*LS$UI"RV&#KJE@FSN4H6OIS4FUC33<TJT;NG:41&%<^>D56K
M5RNFS06.DW6.4J9K!U50BE9<JM#BTT[#B^[9"5.J#8)\ 4IM)4H"$@J$G<@7
MPW$!*G&P#IGP@GX9L!J)!@23L)O DQ#("'PLVN-XBBY:YLTNN6SE,CANLG/9
M'.FL@J4#HK)J%QWT'353,51,Y1$IRFZBB)1#B*SVN9-J*5Y?F8@F=3%(5 R0
M0?ZX0%38WW//"Q^QWE2>_1!N(!O-_P!W^ G\N4?A7M=9-]\U:9"  ;[%G\D
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MJ(V<U]L>THH%,($/9U1. *F.4M7NT7.OVKQ"^RVX%TN7 TS47238/K!!-U+
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M=:6G-[@J4VXDI(N1I%QON#YIJQ^DGN]*KDE*[H/4S!@CSWO<<K0,O?$[Z_\
M(U,>5*F5#!&&'\FQ49OKQ3J[:+#<&!U4A2.[JZEQM$M6H9P &,*:LC6[$LW,
M8JC19%PDFZ%JTG9+D+;H75U>852$K"^Y[YA*"E*ITK*:;400"%>($@D#D1V'
M.:@@@(8,C22DJE,VF"HR=X CK(N,+T34U9KQ9I.>GY.;MUMMDTXD9.5DG#R<
ML=DL,X\,JNX>.53.)"6EY5^Y]3"LY=.5BE(!U#@ R@ANFR^D2TVENGH:-J$
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MRHL)/EL#ZX:2YP2HJ\K[6L8P  C@FP&W+_5'=Q']P^0!N/KL'?Z!Q%W!Y/\
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MLD&I".U!3;D-T"G"O'W"&5\,4N7&@74..OU"PX'EI6L(2@%*B A 3XM5[R
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M;4GJ ;7Q(?8;PS7<4\39G6MH-33\.98<XKFBE3BNZ%2S0TZR$P/LWZIMTF%
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M(.C4XY<@W 2=\65]G?A]YVHXGSQ3>E%'ES-,VHI  6_4(<(!V)*4\@(A0)L
M'M2B ]O<-MP^6X;@ _7;;AK8L;CVX,&.-4O402AO][<NY1 #!N AN41]!#U
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M4M.MM#BP5#OE!"($$R>IZ&9OZ$=<2T@K4"0-X$Q?%04K\2KH>A6Y'<]B;5]
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MU42TM3L9V/,N4(6H.Z9A^AV1]!0M>JD$ZNM8E6Z$DT@X%&P2#AJ+:3DZX"S
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MD:5 @A2?W53S3!VO;&BHIV:A):>:0ZE:-*TK2%(6VK=*TD0L$&"E0((L;6Q
M+*?*XT>95?.YE;'042==J&<C+8V?+5 Z;L3B8781;+K@5')CGZSK+12AS"
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;2>9^GRQ]0>@?X>GY<;/7&<'!@P<&#!P8,?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
